Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
COVID-19

Scott Shepherd, ESMO 2021: The CAPTURE Study: Adaptive Immunity to SARS-CoV-2 Infection and Vaccination in Cancer Patients (Part One)

Copy Link
Published Online: Nov 2nd 2021

touchONCOLOGY joins Dr Scott Shepherd (London, UK), to discuss his presentation at ESMO 2021 on the CAPTURE study exploring adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients. To view Part Two click here.

Questions
1. What were the aims and design of the CAPTURE study? (00:18-02:25)
2. What were the study findings in the infection cohort? (02:25-04:31)
3. What were the study findings in the vaccinated cohort? (04:31-07:18)

Disclosures: Scott Shepherd has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share this Video
Related Videos In COVID-19
COVID-19, Paediatric Oncology
Developed by Touch
Pamela Kearns: Leading SIOP Europe during the COVID-19 Pandemic
Watch Time: 3 mins

touchONCOLOGY spoke to Professor Pamela Kearns (University of Birmingham, UK) to discuss her experience as President of SIOP Europe during the COVID-19 pandemic, and the biggest achievements of the European paediatric oncology community during that time. Questions How would you describe your experience as the SIOP Europe President (2019–21) and how the COVID-19 pandemic influenced […]

COVID-19, Genitourinary Cancer
Morgan Rouprêt
Developed by Touch
Morgan Rouprêt, ESOU22: What Have We Learned From the COVID-19 Pandemic?
Watch Time: 6 mins

touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss what we have learned from the COVID-19 pandemic, how this has impacted the care of cancer patients and what we can do to move forward. Questions       What was the impact of the COVID-19 pandemic on […]

COVID-19
Mark Lawler, European Cancer Summit 2021: Time To Act: COVID-19 & Cancer Campaign

We were delighted to catch up with Prof Mark Lawler to discuss the challenges that the COVID-19 pandemic has had on cancer care in Europe, and the key objectives and messages of the Time To Act: COVID-19 & Cancer campaign. Questions 1. What has been the impact of the COVID-19 pandemic on cancer screening and […]

Trending In COVID-19:

Pamela Kearns: Leading SIOP Europe during the COVID-19 Pandemic
COVID-19, Paediatric Oncology
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72